Lonigutamab (anti-IGF-1R)

A Subcutaneously Delivered Anti-IGF-1R for Thyroid Eye Disease (TED)

Lonigutamab is a subcutaneously delivered anti-IGF-1R currently being evaluated in a Phase 1 study for Thyroid Eye Disease – a greater than $4 billion estimated market opportunity – with potential implications for efficacy, safety, and administration benefits for patients relative to the current standard of care.
A Subcutaneously Delivered Anti-IGF-1R for Thyroid Eye Disease (TED)
Indications

Thyroid Eye Disease

Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, Graves’ ophthalmopathy, or Graves’ orbitopathy, is a debilitating and painful autoimmune disease that causes eye bulging and vision change. In serious cases, TED can lead to loss of vision and blindness. The primary pathophysiology of TED is thought to occur via activating autoantibodies to thyrotropin receptors (TSHRs) on orbital fibroblasts.

*Izokibep is not yet approved for use in any indication.
News Center

The Latest Company
Announcements and Resources